Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-19
2011-04-19
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S474000
Reexamination Certificate
active
07928096
ABSTRACT:
The present invention provides compound of the formula (I):in which at least two of R1, R2, R3, R4, R5, and R6are N2O2M and related compounds, substrates, compositions, and methods of using such compounds and compositions to treat biological disorders in which a polyphasic release of nitric oxide would be beneficial.
REFERENCES:
patent: 5155137 (1992-10-01), Keefer et al.
patent: 5250550 (1993-10-01), Keefer et al.
patent: 5366997 (1994-11-01), Keefer et al.
patent: 5587451 (1996-12-01), Athey et al.
patent: 5650447 (1997-07-01), Keefer et al.
patent: 5721365 (1998-02-01), Keefer et al.
patent: 5731305 (1998-03-01), Keefer et al.
patent: 5910316 (1999-06-01), Keefer et al.
patent: 7067507 (2006-06-01), Pulley et al.
patent: WO 98/13358 (1998-04-01), None
patent: WO 01/92215 (2001-12-01), None
Akaike et al. FASEB Journal, 2000, 14, 1447-54.
Pluta et al. Review on Recent Clinical Trials, 2007, 2, 59-67.
Leyen et al. European Journal of Clinical Pharamacology, 2006, 62, 83-89.
Hassan et al. Disease Markers, 2002, 18, 137-42.
Solomon et al. Heart, 2003, 89, 251-54.
Wallace et al. Expert Opinion on Investigative Drugs, 1997, 6(5), 53-38.
Xu et al. Cell Research, 2002, 12 (5-6), 311-20.
Trafton. “Nitric oxide shown to cause colon cancer”, http://web.mit.edu
ewsoffice/2009/colon-cancer-0119.html, accessed Mar. 30, 2010.
Wang et al. Eye and Contact Lens, 2008, 34(4), 195-7.
Ishii et al. FASEB Journal, 2000, 14, 1485-89.
Prozialeck et al. Toxicological Sciences, 2008, 102(2), 207-18.
Ito et al. Current Neurovascular Research, 2010, 7, 23-31.
Weller. Journal of Investigative Dermatology, 2009, 129, 2335-37.
Gelb et al. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 737-741.
“Cancer Prevention Overview”, http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient, accessed Apr. 9, 2010.
“Erectile dysfunction Prevention”, http://www.mayoclinic.com/health/erectile-dysfunction/DS00162/DSECTION=prevention, accessed Apr. 9, 2010.
“Overview of HIV infection”, http://www.avert.org/prevent-hiv.htm, Accessed Apr. 9, 2010.
“Restenosis Prevention”, http://www.news-medical.net/health/Restenosis-Prevention.aspx, accessed Apr. 2010.
“Aneurysms and Subarachnoid Hemorrhage”, http://www.cedars-sinai.edu/Patients/Programs-and-Servic...oke-Resources/Aneurysms-and-Subarachnoid-Hemorrhage.aspx, accessed Apr. 9, 2010.
“Heavy Metal Toxicity, Mercury Toxicity”, http://www.drcranton.com/mercury.htm, accessed Apr. 9, 2010.
“Intestinal Ischemia and infarction”, http://www.webmd.com/digestive-disorders/intestinal—ischemia—infarction, accessed Apr. 9, 2010.
“Syphilis-Prevention”, http://www.webmd.com/sexual-conditions/tc/syphilis-prevention?print=true, accessed Apr. 9, 2010.
Lazar et al. Letters in Applied Microbiology, 2008, 46, pp. 688-692.
Napoli et al. Proceedings of the National Academy of Sciences, 2001, 98(5), pp. 2860-2864.
Atkins et al., “Macrocyclic Polyamines: 1,4,7,10,13,16-Hexaäzacycloöctadecane”Organic Synthesis, Collective vol. VI, 652-661 (1988).
Barefield et al., “Synthesis of Macrocyclic Tetramines by Metal Ion Assisted Cyclization Reactions”Inorg. Chem., 15 (6), 1370-1377 (1976).
Bellouard et al., “cis-Diprotected Cyclams and Cyclens: a New Route to Symmetrically or Asymmetrically 1,4-Disubstituted Tetraazamacrocycles and to Asymmetrically Tetrasubstituted Derivatives”J. Chem. Soc., Perkin Trans. 1, 3499-3505 (1999).
Bender et al., “The mono-functionalization of symmetrical polyamines,”Tetrahedron, 58, 3111-3128 (2002).
Boldrini et al., “ExpeditiousN-Monoalkylation of 1,4,7,10-Tetraazacyclododecane (cyclen)via Formamido Protection”Tetrahedron Letters, 41, 6527-6530 (2000).
Bridger et al., “A Vertsatile Intermediate for the Preparation of C-Functionalized Azamacrocycles and Application to the Synthesis of the Potent Anti-HIV Agent,”J. Org. Chem., 61, 1519-1522 (1996).
Drago et al., “The Reaction of Nitrogen(II) Oxide with Various Primary and Secondary Amines”J. Am. Chem. Soc., 83, 1819-1822 (Apr. 20, 1961).
Hrabie et al., “New Nitric Oxide-Releasing Zwitterions Derived from Polyamines”J. Org. Chem., 58, 1472-1476 (1993).
Hrabie et al., “Adducts of Piperazine with Nitric Oxide”Org. Prep. and Proc. Int., 31 (2), 189-192 (1999).
Kovacs et al., “pH Controlled Selective Protection of Polyaza Macrocycles”Synthesis, 759-763 (Jul. 1997).
Krakowiak et al., “A New Building Block Method to Synthesize Symmetrical and Asymmetrical Per-N-alkyl-Substituted Polyaza-Crown Compounds,”J, Org. Chem, 54, 4061-4067 (1989).
Lewis et al., “Efficient N- and C-functionalisation of cyclam macrocycles utilizing bisaminal methodology,”Tetrahedron Letters, 45, 3059-3062 (2004).
Longhi et al., “Reactions of Nitrogen (II) Oxide with Miscellaneous Lewis Bases”Inorg. Chem., 1 (4), 768-770 (Nov. 1962).
Meunier et al., “Synthesis and Characterization of Various Unsubstituted and Mono-N-Substituted Tetraazamacrocycles”Can. J. Chem., 73, 685-695 (1995).
Militsopoulou et al., “Simple Synthesis of Cyclic Polyamines Using Selectively N-Tritylated Polyamines and Succinic Anhydride”Tetrahedron Letters, 43, 2593-2596 (2002).
McMurray et al., “Synthesis of 2-(p-Thiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic Acid: Application of the 4-Methoxy-2,3,6-trimethylbenzenesulfonamide Protecting Group in the Synthesis of Macrocyclic Polyamines,”Bioconjugate Chem., 4, 236-245 (1993).
Moi et al., “The Peptide Way to Macrocyclic Bifunctional Chelating Agents: Synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′”-tetraacetic Acid and Study of Its Yttrium (III) Complex,J. Am. Chem. Soc, 110, 6266-6267 (1988).
Nittymaki et al., “Preparation of Azacrown-Functionalized 2′-O-Methyl Oligoribonucleotides, Potential Artificial RNases,”Bioconjugate Chem., 15, 174-184 (2004).
Panetta et al., “Triflamides for Protection and Cyclization of Tetraamines to Tetraazamacrocycles”Tetrahedron Letters, 33 (38), 5505-5508 (1992).
Parker et al., “A practical method for building linear and cyclic triamines from (2-trimethylsilyl)ethanesulfonamides (SES-amides),”Tetrahedron, 59, 10165-10171 (2003).
Reed et al.,Organic Synthesis, 78, 73-81 (2000).
Takenouchi et al., “Novel Pendant-Type Macrocyclic Bifunctional Chelating Agents: (Carboxymethyl) amino Derivatives of 2-(4-Nitrobenzyl)-1,4,7,10-tetraazacyclo-dodecane-N,N′,N″,N′”-tetraacetic Acid and Their Complex Formation with Yttrium (III),J. Org. Chem., 58, 6895-6899 (1993).
Tamara et al.,Tanpakushitsu Kakusan Koso, Bessatsu, 76(5), 225-240 (1976) (based on HCAPlus record).
Wagler et al., “Synthesis of an Optically Active C-Functionalized Cyclam: (S)-5-(Hydroxymethyl)-1,4,8,11-tetra-azacyclotetradecane and its Nickel(II) Complex,,”J. Chem. Soc., Chem. Commun., 277-278 (1987).
Wayland et al., Reactions of Nitric Oxide with Cobalt(ii) Tetraphenylporphyrin: A Unique Bis Nitric Oxide Complex,:J.C.S. Chem. Comm, 24, 1015-1016 (1976).
Yang et al., “Facile N-1 Protection of Cyclam, Cyclen and 1,4,7-Triazacyclononane”Tetrahedron Letters, 44, 2481-2483 (2003).
Guidotti et al., Nitric Oxide Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice,J. Exp. Med., vol. 191, No. 7, pp. 1247-1252, Apr. 3, 2000.
Jenkins et al., Roles of Nitric Oxide in Tumor Growth,Proc. Natl. Acad. Sci. USA, vol. 92, pp. 4392-4396, May 1995.
Pervin et al., Potentiation of Nitric Oxide-Induced Apoptosis of MDA-MB-468 Cells by Farnesyltransferase Inhibitor: Implications in Breast Cancer,Cancer Research, vol. 61, pp. 4701-4706, Jun. 15, 2001.
Shami et al., JS-K, a Glutathione/Glutathione S-Transferase-activated Nitric Oxide Donor of the Diazeniumdiolate Class with Potent Antine
De Rosa Frank
Hrabie Joseph A.
Kapur Preeya
Keefer Larry K.
Waterhouse David J.
Jarrell Noble
Leydig , Voit & Mayer, Ltd.
The United States of America, as represented by the Secretary, D
LandOfFree
Polydiazeniumdiolated cyclic polyamines with polyphasic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polydiazeniumdiolated cyclic polyamines with polyphasic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polydiazeniumdiolated cyclic polyamines with polyphasic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717686